会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ELECTRONIC FLUID TREATMENT APPARATUS AND METHOD
    • 电子流体处理设备和方法
    • WO2009156840A3
    • 2010-10-14
    • PCT/IB2009006065
    • 2009-06-26
    • CONEQUIPT CCVROOM IAN DOUGLASCOOPER MARK BADEN
    • VROOM IAN DOUGLASCOOPER MARK BADEN
    • C02F1/461B03C3/68B03C5/02
    • B03C5/02A61L9/16B03C3/68C02F1/46109C02F1/4672C02F2001/46123C02F2001/46138C02F2103/008C02F2201/46175
    • Electronic fluid treatment apparatus is provided comprising an electrode assembly (5) mounted in a housing (9, 15) having an inlet (10, 16) and an outlet (11, 17, 18). The electrode assembly has multiple electrodes (1 ) held in parallel spaced relationship relative to each other. A power supply (8) is connected to the electrodes such that alternate electrodes are interconnected so as to be similarly energised by the power supply. The power supply is adapted to provide a pulsed voltage at an amplitude and frequency dependent on the construction of the individual electrodes, the spacing between them and the dielectric properties of the fluid in which the electrodes are to operate such that the electrodes, in use, provide a capacitive effect. Typically an inductance is connected in parallel with the electrodes so as to create a resonant circuit. The apparatus is able to provide three distinct actions against microorganisms contained in the fluid.
    • 提供电子流体处理设备,其包括安装在具有入口(10,16)和出口(11,17,18)的壳体(9,15)中的电极组件(5)。 电极组件具有多个电极(1),彼此保持平行间隔的关系。 电源(8)连接到电极,使得交替电极互连以类似地由电源供电。 电源适于以取决于单个电极的结构,它们之间的间隔和其中电极将要操作的流体的介电特性的幅度和频率提供脉冲电压,使得在使用中的电极, 提供电容效应。 通常,电感与电极并联连接以产生谐振电路。 该装置能够提供针对流体中包含的微生物的三种不同的作用。
    • 2. 发明申请
    • ELECTRONIC FLUID TREATMENT APPARATUS AND METHOD
    • 电子流体处理设备和方法
    • WO2009156840A2
    • 2009-12-30
    • PCT/IB2009/006065
    • 2009-06-26
    • CONEQUIPT CCVROOM, Ian, DouglasCOOPER, Mark, Baden
    • VROOM, Ian, DouglasCOOPER, Mark, Baden
    • C02F1/461B03C5/02
    • B03C5/02A61L9/16B03C3/68C02F1/46109C02F1/4672C02F2001/46123C02F2001/46138C02F2103/008C02F2201/46175
    • Electronic fluid treatment apparatus is provided comprising an electrode assembly (5) mounted in a housing (9, 15) having an inlet (10, 16) and an outlet (11, 17, 18). The electrode assembly has multiple electrodes (1 ) held in parallel spaced relationship relative to each other. A power supply (8) is connected to the electrodes such that alternate electrodes are interconnected so as to be similarly energised by the power supply. The power supply is adapted to provide a pulsed voltage at an amplitude and frequency dependent on the construction of the individual electrodes, the spacing between them and the dielectric properties of the fluid in which the electrodes are to operate such that the electrodes, in use, provide a capacitive effect. Typically an inductance is connected in parallel with the electrodes so as to create a resonant circuit. The apparatus is able to provide three distinct actions against microorganisms contained in the fluid.
    • 提供电子流体处理设备,其包括安装在具有入口(10,16)和出口(11,17,18)的壳体(9,15)中的电极组件(5)。 电极组件具有多个电极(1),彼此保持平行间隔的关系。 电源(8)连接到电极,使得交替电极互连以类似地由电源供电。 电源适于以取决于单个电极的结构,它们之间的间隔和其中电极将要操作的流体的介电特性的幅度和频率提供脉冲电压,使得在使用中的电极, 提供电容效应。 通常,电感与电极并联连接以产生谐振电路。 该装置能够提供针对流体中包含的微生物的三种不同的作用。
    • 5. 发明申请
    • LONG-TERM IN VIVO TRANSGENE EXPRESSION
    • VIVO TRANSGENE EXPRESSION的长期使用
    • WO2009036280A1
    • 2009-03-19
    • PCT/US2008/076177
    • 2008-09-12
    • COPERNICUS THERAPEUTICS, INC.COOPER, Mark J.PADEGIMAS, Linas
    • COOPER, Mark J.PADEGIMAS, Linas
    • C12N15/85
    • C07K14/4712A61K48/0066C12N15/85C12N2799/04C12N2830/42C12N2830/50C12N2830/85C12N2840/00C12N2840/85
    • Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3'BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3' BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.
    • 有效和长期的hCFTR表达是囊性纤维化肺部治疗的主要障碍之一。 hCFTR mRNA表达水平取决于真核表达盒组分,原核骨架元素,基因转移方法也可能影响转录沉默机制。 制备了密码子优化和CpG还原的人CFTR基因(CO-CFTR)。 测试各种载体修饰以促进CO-CFTR表达的延长的持续时间。 以倒置方向插入延伸的3'BGH转录序列(712bp)产生CO-CFTR表达在生物相关水平上的延长表达。 进一步的研究表明,延长的CO-CFTR表达依赖于扩展的BGH 3'BGH转录序列的方向及其转录,对UbC启动子不是特异性的,并且较少依赖于其它载体骨架元素。
    • 7. 发明申请
    • CODON OPTIMIZED CFTR
    • WO2008045548A2
    • 2008-04-17
    • PCT/US2007021862
    • 2007-10-12
    • COPERNICUS THERAPEUTICS INCCOOPER MARK JPADEGIMAS LINAS
    • COOPER MARK JPADEGIMAS LINAS
    • A61K48/00
    • C07K14/4712A61K48/005C12N2830/50C12N2840/44
    • A synthetic hCFTR DNA sequence has been developed that produces remarkably high levels of hCFTR mRNA and protein in dosed murine lungs and human cells in culture compared to the natural hCFTR cDNA. This synthetic DNA addresses.problems inherent in some natural cDNAs, such as premature transcriptional truncation sites introduced during cDNA synthesis. Introns are initially present in mRNA until the mRNA is processed. cDNA made from processed mRNA is devoid of introns. Thus DNA sequences (exon junctions) are present in a cDNA molecule which are not present in cells in nature. These exon junctions may affect transcription. Methods for improving expression of CFTR are based on sequence changes in cDNA molecules. The improvement methods may be applied to other cDNA molecules which are refractory to in vivo expression efforts. Compositions embodying the sequence changes increase the production of both transgenic mRNA and protein from cDNA molecules.
    • 已经开发了合成的hCFTR DNA序列,其与天然hCFTR cDNA相比在培养的给药鼠肺和人细胞中产生显着高水平的hCFTR mRNA和蛋白质。 这种合成的DNA解决了一些天然cDNA中固有的问题,例如在cDNA合成期间引入的早期转录截短位点。 内含子最初存在于mRNA中直到mRNA被加工。 由加工的mRNA制成的cDNA没有内含子。 因此,DNA序列(外显子连接)存在于自然界中不存在于细胞中的cDNA分子中。 这些外显子可能会影响转录。 改进CFTR表达的方法是基于cDNA分子的序列变化。 改进方法可以应用于对体内表达努力难以进行的其它cDNA分子。 体现序列变化的组合增加了来自cDNA分子的转基因mRNA和蛋白质的产生。
    • 10. 发明申请
    • PLANT BREEDING METHOD
    • 植物育种方法
    • WO2005000006A2
    • 2005-01-06
    • PCT/US2004/016850
    • 2004-05-27
    • PIONEER HI-BRED INTERNATIONAL, INC.SMITH, Oscar, S.COOPER, MarkTINGEY, Scott, V.RAFALSKI, Antoni, J.LUEDTKE, RoyNIEBUR, William, S.
    • SMITH, Oscar, S.COOPER, MarkTINGEY, Scott, V.RAFALSKI, Antoni, J.LUEDTKE, RoyNIEBUR, William, S.
    • A01H
    • A01H1/04A01H1/02A01H5/10
    • Methods for using genetic marker genotype (e.g., gene sequence diversity information) to improve the process of developing plant varieties (e.g., single cross hybrids) with improved phenotypic performance are provided. Methods for predicting the value of a phenotypic trait in a plant are provided. The methods use genotypic, phenotypic, and optionally family relationship information for a first plant population to identify an association between at least one genetic marker and the phenotypic trait, and then use the association to predict the value of the phenotypic trait in one or more members of a second, target population of known marker genotype. Methods for identifying new allelic variants affecting the trait are also provided. Plants selected, provided, or produced by any of the methods herein, transgenic plants created by any of the methods herein, and digital systems for performing the methods herein are also provided.
    • 提供了使用遗传标记基因型(例如,基因序列多样性信息)来改进具有改进的表型性能的开发植物品种(例如,单杂交杂交)的过程的方法。 提供了预测植物表型性状价值的方法。 所述方法使用第一植物群体的基因型,表型和任选的家族关系信息来鉴定至少一个遗传标记和表型性状之间的关联,然后使用该关联来预测一个或多个成员中的表型性状的价值 的第二个已知标记基因型的目标群体。 还提供了确定影响性状的新的等位基因变异体的方法。 本文中通过任何方法选择,提供或产生的植物,通过本文的任何方法产生的转基因植物和用于执行本文方法的数字系统也被提供。